feisty
Peptides for menopause sit in an interesting place right now: too new to be mainstream, too well-studied to dismiss. These short chains of amino acids act as biological messengers, telling cells to do specific things, and several of them directly interact with the hormonal and metabolic shifts that arrive with the menopause transition. This isn't a fringe wellness category anymore. Researchers are actively investigating peptides for sleep, bone density, body composition, skin integrity, and mood, all of which are areas that falling oestrogen disrupts. What follows is a plain account of 7 peptides with the most relevant evidence for menopausal women, plus an honest note on what the research still doesn't know.
What peptides actually are (and aren't)
A peptide is a molecule made of two or more amino acids linked together. Your body produces thousands of them naturally. Some act as hormones (insulin is a peptide). Others act as growth factors or neurotransmitters. The peptides discussed below are either bioidentical to naturally occurring sequences or synthetic analogues designed to mimic a biological function. They're not steroids, they don't work like HRT, and they don't replace oestrogen. They work on specific receptors and pathways, which is why the effects are targeted rather than systemic.
Most therapeutic peptides are injected subcutaneously because stomach acid breaks them down before they can be absorbed orally. Some newer formulations use nasal sprays or transdermal patches with varying results. This is worth flagging early: the delivery method matters as much as the peptide itself.
The 7 peptides most relevant to menopause
1. BPC-157 (body protection compound)
BPC-157 is a 15-amino-acid sequence derived from a protein found in gastric juice. The research on it is primarily animal-based, but the results are consistent enough to attract clinical interest. BPC-157 appears to accelerate tendon and ligament healing, reduce gut inflammation, and support dopamine and serotonin signalling. For menopausal women dealing with gluteal tendinopathy or other joint issues driven by oestrogen loss, the tendon-repair angle is the most compelling. Human trials are limited, so it sits in the "promising but wait for more data" category.
2. CJC-1295 and Ipamorelin (growth hormone secretagogues)
These two are almost always discussed together because they're typically used in combination. CJC-1295 is a growth hormone-releasing hormone analogue. Ipamorelin is a growth hormone-releasing peptide. Used together, they stimulate the pituitary gland to release more growth hormone in a pulse pattern that mimics natural secretion. Growth hormone declines with age, and that decline accelerates around menopause. The effects researchers have documented include improved sleep quality (particularly slow-wave sleep), reduced visceral fat, and preserved lean muscle mass. Those are three of the most common complaints in the menopause transition. The safety profile in adults appears reasonable at prescribed doses, but neither peptide is TGA-approved in Australia for menopause specifically.
3. Epithalon (Epitalon)
Epithalon is a tetrapeptide (four amino acids) originally developed in Russia at the St. Petersburg Institute of Bioregulation and Gerontology. Its proposed mechanism involves activation of telomerase, the enzyme that maintains telomere length. Shorter telomeres are associated with accelerated cellular ageing, and oestrogen appears to have a protective effect on telomere length. When oestrogen drops, that protection reduces. Epithalon has shown anti-ageing effects in animal and some limited human studies, including improved sleep, antioxidant activity, and melatonin regulation. The melatonin connection is particularly relevant: disrupted sleep is one of the most damaging and least-treated aspects of the menopause transition.
4. Thymosin Beta-4 (TB-500)
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide found in high concentrations in blood platelets. Its main function is to promote cell migration and differentiation, which underlies wound healing and tissue repair. For menopausal women, the most relevant application is skin integrity. Collagen loss after menopause is rapid: women lose up to 30 percent of skin collagen in the first 5 years post-menopause. TB-500 appears to stimulate collagen synthesis and support angiogenesis (the formation of new blood vessels), which matters for skin, hair follicles, and joint tissue. Human data is thin, but the mechanistic rationale is sound.
5. PT-141 (Bremelanotide)
PT-141 is the one peptide on this list with FDA approval. It's approved in the United States under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, though clinicians use it off-label for postmenopausal women too. PT-141 works on melanocortin receptors in the brain rather than directly on genital tissue, which makes it mechanistically different from topical oestrogen or lubricants. It increases sexual desire centrally. This distinction matters because sex after menopause involves both physical changes (vaginal dryness, reduced blood flow) and central changes (libido, arousal). PT-141 addresses the central side. It's delivered via subcutaneous injection before anticipated sexual activity. Side effects include transient nausea and facial flushing.
6. Selank
Selank is a heptapeptide (seven amino acids) developed in Russia as an anxiolytic. It modulates the expression of brain-derived neurotrophic factor (BDNF) and appears to reduce anxiety without the sedation or dependence associated with benzodiazepines. Its relevance to menopause is direct: anxiety disorders increase significantly during perimenopause, and the brain fog, low mood, and heightened stress response that many women experience are partly driven by oestrogen's declining influence on GABA receptors. Selank also appears to have mild nootropic effects, which makes it relevant for cognitive complaints. Available research is primarily from Russian institutions, which limits independent replication, but the mechanistic pathway is credible.
7. GHK-Cu (copper peptide)
GHK-Cu is a naturally occurring copper-binding peptide found in human plasma, saliva, and urine. It's the most studied peptide in skincare, and the results are more than cosmetic. GHK-Cu stimulates collagen and elastin synthesis, reduces inflammation, and activates genes associated with tissue repair and antioxidant defence. Oestrogen decline accelerates the collagen breakdown GHK-Cu counteracts, which is why the research on it is particularly relevant to menopausal skin and wound healing. Unlike most other peptides on this list, GHK-Cu is available in topical formulations at concentrations that studies suggest are clinically meaningful (typically 1 to 3 percent). It doesn't require injection and doesn't carry the regulatory ambiguity of injectable peptides in Australia.
What the evidence doesn't yet confirm
Most peptide research involves animal models, small human cohorts, or studies funded by manufacturers. That doesn't make the findings wrong, but it does mean the effect sizes seen in controlled trials may not translate directly to real-world use. Dosing protocols vary significantly between practitioners, compounding pharmacies, and products, and there's no standardised guidance in Australia for most of these compounds.
Peptides also don't exist in isolation. Their effects interact with sleep, nutrition, exercise load, and existing hormone levels. A woman on MHT will have a different response profile than one managing symptoms without it. This is not a category where self-prescribing makes sense. A practitioner with actual peptide experience, not just general wellness knowledge, is worth finding before starting.
For context on where peptides fit relative to other options, the evidence base for natural menopause treatments provides a useful comparison point. Some of those options have decades of robust human trial data behind them. Peptides, with a few exceptions, are earlier in that process.
Practical considerations before starting
Sourcing matters. In Australia, most injectable peptides are available only through compounding pharmacies on a prescription basis. Quality control varies between compounders, and the TGA does not specifically regulate compounded peptides the same way it regulates registered medicines. This means purity and concentration can differ between suppliers.
Cost is real. A single month of CJC-1295 and Ipamorelin from a reputable Australian compounding pharmacy typically runs between $150 and $350 AUD, depending on dose. GHK-Cu topicals are more accessible, starting around $60 to $90 for a quality serum. PT-141 sits in the middle range.
Start with the question of what you're actually trying to address. Sleep, body composition, skin, libido, anxiety, and joint recovery all point toward different peptides. Using one to solve all of them isn't how the biology works.